-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target

Benzinga·04/29/2025 17:41:01
Listen to the news
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $27 price target.